Results 231 to 240 of about 2,804,111 (259)

Proposed new diagnostic criteria for chronic migraine

Cephalalgia, 2020
Introduction ICHD-3 criteria for chronic migraine (CM) include a mixture of migraine and tension-type-like headaches and do not account for patients who have a high frequency of migraine but no other headaches.
M. A. Chalmer, T. Hansen, E. Lebedeva, D. Dodick, R. Lipton, J. Olesen   +5 more
semanticscholar   +1 more source

Predictors of episodic migraine transformation to chronic migraine: A systematic review and meta-analysis of observational cohort studies

Cephalalgia, 2020
Background and purpose An estimated 2.5–3.1% of people with episodic migraine develop chronic migraine in a year. Several risk factors are associated with an increased risk for this transformation.
Jingjing Xu, Fanyi Kong, D. Buse
semanticscholar   +1 more source

Cortical morphological changes in chronic migraine in a Taiwanese cohort: Surface- and voxel-based analyses

Cephalalgia, 2020
Background Previous voxel- or surface-based morphometric analysis studies have revealed alterations in cortical structure in patients with chronic migraine, yet with inconsistent results.
K. Lai, D. Niddam, J. Fuh, Wei-Ta Chen, Jaw‐Ching Wu, Shuu-Jiun Wang   +5 more
semanticscholar   +1 more source

Erenumab and OnabotulinumtoxinA Combination Therapy for the Prevention of Intractable Chronic Migraine without Aura: A Retrospective Analysis

Journal of Pain & Palliative Care Pharmacotherapy, 2020
Erenumab is a monoclonal antibody that mediates calcitonin-gene-related peptide (CGRP), a pro-inflammatory polypeptide implicated in migraine pathology, by targeting its receptor.
M. Armanious, N. Khalil, Yuanyuan Lu, Rebecca Jimenez-Sanders   +3 more
semanticscholar   +1 more source

Erenumab in the prevention of high‐frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real‐life study

Headache, 2020
To assess the effectiveness, safety, and tolerability of erenumab in a real‐life migraine population, while trying to identify responsiveness predictors.
P. Barbanti, C. Aurilia, G. Egeo, L. Fofi, S. Cevoli, B. Colombo, M. Filippi, F. Frediani, Frances A. Bono, L. Grazzi, Antonio Salerno, B. Mercuri, Antonio Carnevale, C. Altamura, F. Vernieri   +14 more
semanticscholar   +1 more source

Erenumab in Chronic Migraine: An Australian Experience

Headache, 2020
To determine the effectiveness and safety of erenumab in patients with chronic migraine in the real‐world setting of 3 headache centers in Australia.
Shuli Cheng, B. Jenkins, Nicole Limberg, E. Hutton   +3 more
semanticscholar   +1 more source

Patient-Centered Treatment of Chronic Migraine With Medication Overuse

Neurology, 2022
T. Schwedt, J. Hentz, S. Sahai-Srivastava, N. Murinova, Nicole Spare, Christina Treppendahl, V. Martin, Marius Birlea, K. Digre, David B Watson, Michael Leonard, Teri Robert, D. Dodick   +12 more
semanticscholar   +1 more source

Effectiveness of ketogenic diet in treatment of patients with refractory chronic migraine

Neurological Sciences, 2021
D. Bongiovanni, C. Benedetto, S. Corvisieri, C. del Favero, F. Orlandi, G. Allais, Silvia Sinigaglia, M. Fadda   +7 more
semanticscholar   +1 more source

Real-life assessment of erenumab in refractory chronic migraine with medication overuse headache

Neurological Sciences, 2021
Umberto Pensato, C. Baraldi, V. Favoni, M. Cainazzo, P. Torelli, Pietro Querzani, A. Pascazio, Davide Mascarella, Eleonora Matteo, Simone Quintana, G. Asioli, P. Cortelli, G. Pierangeli, S. Guerzoni, S. Cevoli   +14 more
semanticscholar   +1 more source

Onconephrology: The intersections between the kidney and cancer

Ca-A Cancer Journal for Clinicians, 2021
Kenar D Jhaveri, Mark A Perazella
exaly